GPCR crystal structures: Medicinal chemistry in the pocket

被引:87
作者
Shonberg, Jeremy [1 ]
Kling, Ralf C. [1 ]
Gmeiner, Peter [1 ]
Loeber, Stefan [1 ]
机构
[1] Univ Erlangen Nurnberg, Emil Fischer Ctr, Dept Chem & Pharm, D-91052 Erlangen, Germany
关键词
GPCR; Medicinal chemistry; Crystal structure; Drug discovery; Receptor activation; Ligand-receptor interactions; Receptor selectivity; PROTEIN-COUPLED RECEPTORS; NOCICEPTIN/ORPHANIN FQ RECEPTOR; BETA-ADRENOCEPTOR AGONISTS; STRUCTURE-BASED DISCOVERY; DOPAMINE D3 RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; OPIOID RECEPTOR; SMALL-MOLECULE; IN-VITRO; ALLOSTERIC MODULATORS;
D O I
10.1016/j.bmc.2014.12.034
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent breakthroughs in GPCR structural biology have significantly increased our understanding of drug action at these therapeutically relevant receptors, and this will undoubtedly lead to the design of better therapeutics. In recent years, crystal structures of GPCRs from classes A, B, C and F have been solved, unveiling a precise snapshot of ligand-receptor interactions. Furthermore, some receptors have been crystallized in different functional states in complex with antagonists, partial agonists, full agonists, biased agonists and allosteric modulators, providing further insight into the mechanisms of ligand-induced GPCR activation. It is now obvious that there is enormous diversity in the size, shape and position of the ligand binding pockets in GPCRs. In this review, we summarise the current state of solved GPCR structures, with a particular focus on ligand-receptor interactions in the binding pocket, and how this can contribute to the design of GPCR ligands with better affinity, subtype selectivity or efficacy. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3880 / 3906
页数:27
相关论文
共 247 条
[1]   International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy [J].
Abbracchio, Maria P. ;
Burnstock, Geoffrey ;
Boeynaems, Jean-Marie ;
Barnard, Eric A. ;
Boyer, Jose L. ;
Kennedy, Charles ;
Knight, Gillian E. ;
Fumagalli, Marta ;
Gachet, Christian ;
Jacobson, Kenneth A. ;
Weisman, Gary A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :281-341
[2]   Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists [J].
Ahn, HS ;
Arik, L ;
Boykow, G ;
Burnett, DA ;
Caplen, MA ;
Czarniecki, M ;
Domalski, MS ;
Foster, C ;
Manna, M ;
Stamford, AW ;
Wu, YS .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (14) :2073-2078
[3]   Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells [J].
Akbar, GKM ;
Dasari, VR ;
Webb, TE ;
Ayyanathan, K ;
Pillarisetti, K ;
Sandhu, AK ;
Athwal, RS ;
Daniel, JL ;
Ashby, B ;
Barnard, EA ;
Kunapuli, SP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (31) :18363-18367
[4]   Structure-Based and Fragment-Based GPCR Drug Discovery [J].
Andrews, Stephen P. ;
Brown, Giles A. ;
Christopher, John A. .
CHEMMEDCHEM, 2014, 9 (02) :256-275
[5]   In silico directed chemical probing of the adenosine receptor family [J].
Areias, Filipe M. ;
Brea, Jose ;
Gregori-Puigjane, Elisabet ;
Zaki, Magdi E. A. ;
Carvalho, M. Alice ;
Dominguez, Eduardo ;
Gutierrez-de-Teran, Hugo ;
Proenca, M. Fernanda ;
Loza, Maria I. ;
Mestres, Jordi .
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (09) :3043-3052
[6]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[7]   A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor [J].
Bach, Peter ;
Bostrom, Jonas ;
Brickmann, Kay ;
van Giezen, J. J. J. ;
Hovland, Ragnar ;
Petersson, Annika U. ;
Ray, Asim ;
Zetterberg, Fredrik .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (10) :2877-2881
[8]   The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors [J].
Baker, JG .
BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (03) :317-322
[9]   A Full Pharmacological Analysis of the Three Turkey β-Adrenoceptors and Comparison with the Human β-Adrenoceptors [J].
Baker, Jillian G. .
PLOS ONE, 2010, 5 (11)
[10]   The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors [J].
Baker, Jillian G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (05) :1048-1061